Este folleto presenta los datos sobre la mortalidad por ENT y la prevalencia de factores de riesgo de las ENT, para los países en la región de las Américas. Su contenido está enfocado en la agenda 5 x 5 de ENT que incluye las principals ENT (enfermedades cardiovasculares, cáncer, diabetes y enf...ermedades respiratorias crónicas) y la salud mental (suicidio); así como los principales factores de riesgo de ENT (consumo de tabaco, uso no civo del alcohol, dieta p oco s aludable, ac tividad física insuficiente) junto con la contaminación del aire. Incluye información sobre el número y porcentaje de muertes, tasas de mortalidad estandarizadas por edad, muerte prematura por ENT y la prevalencia de los principales factores de riesgo de las ENT.
more
План предназначен как методическое руководство для наиболее приоритетных стран Региона при разработке собственных долго- и краткосрочных национальных планов в о...тношении ТБ, а также послужит руководством к действию для Европейского регионального бюро ВОЗ и всех других партнеров по борьбе с ТБ.
more
Q1: In individuals with psychotic disorders (including schizophrenia), are antipsychotic drugs safe and effective?
Oral Health and Dental Services
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
Reference book specifying the principles of intervention for all food security activities, from initial assessment to programme implementation.
(Published with Decision No. 3003/QðBYT dated 19/8/2009 of the Minister of Health)
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses
Updated March 2018 | Accessed Online March 2018
www.jogh.org • doi: 10.7189/jogh.02.020405 ~ December 2012 • Vol. 2 No. 2 • 020405